Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Clinical trial for solid tumor combination treatment
March 2018
SHARING OPTIONS:

MARSEILLE, France—A clinical trial collaboration is now underway between Innate Pharma SA and MedImmune, the global biologics research and development arm of AstraZeneca. Under the auspices of the deal, the companies will assess the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in a Phase 1/2 study of individuals with select solid tumors. The compound will be tested in combination with Innate’s investigational first-in-class anti-C5aR monoclonal antibody, IPH5401. Innate will conduct the study, with costs shared by both companies. The Phase 1 portion will determine a recommended dose regimen of IPH5401 and durvalumab, while the Phase 2 portion will evaluate safety and efficacy.
 
“Our collaboration with MedImmune provides further evidence of Innate’s commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio,” said Mondher Mahjoubi, CEO of Innate Pharma. “We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.